Recombinant human chorionic gonadotropin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04992468 | Oct 2021 → Apr 2023 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00989781 | Sep 2009 → Sep 2013 | polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00700778 | Jul 2008 → Mar 2014 | BRCA1-related cancer predisposition, female breast carcinoma | Fox Chase Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT03735030 Comparator | Nov 2018 → Aug 2019 | infertility disorder | IBSA Institut Biochimique SA | Completed | Missed primary |
| Phase 2 | NCT00553514 Background | Dec 2007 → Mar 2009 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT00505752 Background | Jan 2007 → Sep 2008 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT02449889 Comparator | Apr 2016 → Jul 2017 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01497197 Background | May 2012 → Jan 2014 | infertility disorder, pituitary deficiency | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 3 | NCT01297465 Background | May 2011 → Oct 2012 | — | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 3 | NCT00747617 Comparator | Sep 2007 → Apr 2010 | polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT04983173 Background | Nov 2021 → Mar 2026 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT01339299 Comparator | Oct 2009 → Jul 2012 | infertility disorder | Regionshospitalet Viborg, Skive | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human chorionic gonadotropin | “Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous...” PMID 35137345 ↗ Feb 202211“Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®)” NCT04983173 ↗ “Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ |
| Known as | hCG | “a recombinant hCG preparation (Ovitrelle®; Reference product).” PMID 35137345 ↗ Feb 2022 |
| Known as | Ovidrel | “A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.” NCT01497197 ↗ |
| Known as | Ovitrelle | “A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.” NCT01497197 ↗3“Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®)” NCT04983173 ↗ “Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ “a recombinant hCG preparation (Ovitrelle®; Reference product).” PMID 35137345 ↗ Feb 2022 |
| Known as | r-hCG | “Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1...” NCT00505752 ↗5“INTERVENTION(S): Blood samples obtained before and 24 hours after injection of 25 μg recombinant hCG (r-hCG).” PMID 24188875 ↗ Nov 2013 “A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.” NCT01497197 ↗ “Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®)” NCT04983173 ↗ “Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ “recombinant human chorionic gonadotropin (r-hCG)” NCT01339299 ↗ |
| Known as | Recombinant hCG | “INTERVENTIONS: For dose-response studies, blood samples were obtained before and at 0.5, 24, and 48 h after iv recombinant hCG (1, 10, 25, 100, and 250 μg).” PMID 21270326 ↗ Jan 20111“a recombinant hCG preparation (Ovitrelle®; Reference product).” PMID 35137345 ↗ Feb 2022 |
| Modality | Protein / enzyme biologic | “Recombinant human chorionic gonadotropin (r-hCG)” NCT00505752 ↗ |
| Route | Subcutaneous | “250 mcg subcutaneously” NCT00553514 ↗ |